Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.51 |
| ▸ | KMO | O15229 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 2/20 | 0.49 |
| ▸ | RXRB | P28702 | 2/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182619 | 0.84 | RXRA (0.53) | RXRARXRB | |
| SCHEMBL4818369 | 0.82 | RAB9A (0.53) | MRGPRX4KMT2ANPC1ALDH1A1RAB9A | |
| SCHEMBL7112190 | 0.81 | ALDH1A1 (0.48) | KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL4815947 | 0.79 | HSD17B1 (0.51) | ALDH1A1 | |
| SCHEMBL4820077 | 0.76 | PPARG (0.67) | — | |
| SCHEMBL30350581 | 0.75 | KMO (0.63) | MRGPRX4KMORXRARXRBLMNA | |
| SCHEMBL29054110 | 0.75 | KMO (0.63) | MRGPRX4KMORXRARXRBLMNA | |
| SCHEMBL16429234 | 0.74 | KMO (0.87) | KMORXRARXRBLMNAGAA | |
| SCHEMBL10012987 | 0.74 | KMO (0.79) | KMORXRARXRBLMNAGAA | |
| SCHEMBL71238 | 0.74 | KMO (0.86) | KMORXRARXRBLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417169-B2 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679304-A1 | AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | ADRB2, ADRA2A, ADRA1A | MRGPRX4 401/4885KMO 1271/4885RXRA 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.